Showing search results for intrinsic factor 1-10 of 185. Intrinsic Factor Blocking Antibody. Intrinsic Factor, produced by cells lining the stomach, binds Vitamin B12 (cyanocobalamin) to facilitate absorption of the vitamin. Hypercoagulability in pregnancy is the propensity of pregnant women to develop thrombosis (blood clots). Pregnancy itself is a factor of hypercoagulability (pregnancy-induced hypercoagulability), as a physiologically adaptive mechanism to prevent post partum bleeding. However, when combined with an additional underlying hypercoagulable states. Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors Clinical Background [return to contents] Thrombophilia is characterized by hypercoagulability and an increased propensity for thrombosis. Almost 2 million Americans succumb annually to a thromboembolic event, 1 with venous thrombosis the third most common cardiovascular disease after ischemic heart disease and stroke. Factor V Leiden (rs6025) is a variant (mutated form) of human factor V (one of several substances that helps blood clot), which causes an increase in blood clotting (hypercoagulability). Blood Clots (Arterial & Venous) Overview. Blood clotting can be and is a very important natural process in which platelets, fibrin, blood cells and various components of blood clump together to stop bleeding after a blood vessel or your skin has been injured. About Akron Children's While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Factor V Leiden (FVL) mutation and prothrombin 20210 (PT 20210) mutation tests are two tests often used together to help diagnose the cause of inappropriate blood clot (thrombus) formation, including deep vein thrombosis (DVT) and/or venous thromboembolism (VTE). Most patients with venous thromboembolism do not require thrombophilia testing, since the results will not affect management. Testing may be considered in younger patients with weak provoking. Introduction. Tens of millions of patients worldwide are on short- or long-term anticoagulant therapy. A variety of fast-acting and extended prophylaxis agents are available, all of which may be associated with bleeding complications.